I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional outside the UK and Australia:

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Gastrointestinal (GI) cancers

Gastrointestinal cancers, including hepatocellular carcinoma, colorectal, esophageal and gastric cancers, are among the most commonly diagnosed cancers worldwide and current global statistics rank these malignancies as the leading causes of cancer deaths worldwide.

As 5-year survival rates for GI cancers are among the lowest among major tumor types, they comprise some of the world’s largest areas of unmet need in Oncology.

What's new
Upcoming congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Educational Materials

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

IMbrave150 is a global Phase III, multicentre, open-label study of 501 people with unresectable HCC who have not received prior systemic therapy. People were randomised 2:1 to receive the combination of atezolizumab and bevacizumab or sorafenib. Results of IMbrave150 have been published in New England Journal of Medicine (NEJM).

Ask a question or share feedback